Literature DB >> 12844330

MAP kinase phosphatase 1: a novel mediator of biological effects of glucocorticoids?

A R Clark1.   

Abstract

Synthetic glucocorticoids (GCs) potently inhibit the expression of pro-inflammatory genes and are widely used in the treatment of inflammatory diseases. However, some patients are resistant to the therapeutic effects of GCs, and many suffer deleterious side effects from these drugs. Furthermore, the precise mechanisms by which GCs inhibit pro-inflammatory gene expression remain unclear. A number of recent papers report that GCs induce the sustained expression of MAP kinase (MAPK) phosphatase 1 (MKP-1), a negative regulator of MAPK signal transduction pathways. The potential relevance of MKP-1 to some of the biological effects of GCs is discussed.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12844330     DOI： 10.1677/joe.0.1780005

Source DB:  PubMed          Journal:  J Endocrinol        ISSN： 0022-0795            Impact factor:   4.286


  50 in total

Review 1.  A role for corticosterone in impaired intestinal immunity and barrier function in a rodent model of acute alcohol intoxication and burn injury.

Authors:  Mashkoor A Choudhry; Xiaoling Li; Irshad H Chaudry
Journal:  J Neuroimmune Pharmacol       Date:  2006-12       Impact factor: 4.147

Review 2.  A Holy Grail of asthma management: toward understanding how long-acting beta(2)-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids.

Authors:  M A Giembycz; M Kaur; R Leigh; R Newton
Journal:  Br J Pharmacol       Date:  2007-12-10       Impact factor: 8.739

3.  Dual-specificity phosphatase 1 as a pharmacogenetic modifier of inhaled steroid response among asthmatic patients.

Authors:  Ying Jin; Donglei Hu; Edward L Peterson; Celeste Eng; Albert M Levin; Karen Wells; Kenneth Beckman; Rajesh Kumar; Max A Seibold; Gloria Karungi; Amanda Zoratti; John Gaggin; Janis Campbell; Joshua Galanter; Rocío Chapela; José R Rodríguez-Santana; H Geoffrey Watson; Kelley Meade; Michael Lenoir; William Rodríguez-Cintrón; Pedro C Avila; David E Lanfear; Esteban G Burchard; L Keoki Williams
Journal:  J Allergy Clin Immunol       Date:  2010-07-31       Impact factor: 10.793

Review 4.  Protective autoantibodies in the rheumatic diseases: lessons for therapy.

Authors:  Gregg J Silverman; Jaya Vas; Caroline Grönwall
Journal:  Nat Rev Rheumatol       Date:  2013-03-19       Impact factor: 20.543

5.  Absence of glucocorticoids augments stress-induced Mkp1 mRNA expression within the hypothalamic-pituitary-adrenal axis.

Authors:  Chad D Osterlund; Vanessa Thompson; Laura Hinds; Robert L Spencer
Journal:  J Endocrinol       Date:  2013-11-28       Impact factor: 4.286

Review 6.  Mechanistic systems biology of inflammatory gene expression in airway smooth muscle as tool for asthma drug development.

Authors:  Chi-Ming Hai
Journal:  Curr Drug Discov Technol       Date:  2008-12

Review 7.  Neuroendocrine-immune interactions in rheumatoid arthritis: mechanisms of glucocorticoid resistance.

Authors:  Marni N Silverman; Esther M Sternberg
Journal:  Neuroimmunomodulation       Date:  2008-07-29       Impact factor: 2.492

8.  Inhibition of protein tyrosine phosphatases prevents mesenteric lymph node T-cell suppression following alcohol intoxication and burn injury.

Authors:  Xiaoling Li; Martin G Schwacha; Irshad H Chaudry; Mashkoor A Choudhry
Journal:  J Burn Care Res       Date:  2008 May-Jun       Impact factor: 1.845

9.  Glucocorticoid regulation of mouse and human dual specificity phosphatase 1 (DUSP1) genes: unusual cis-acting elements and unexpected evolutionary divergence.

Authors:  Carmen R Tchen; Joana R S Martins; Nasren Paktiawal; Roberta Perelli; Jeremy Saklatvala; Andrew R Clark
Journal:  J Biol Chem       Date:  2009-11-23       Impact factor: 5.157

10.  BOL-303242-X, a novel selective glucocorticoid receptor agonist, with full anti-inflammatory properties in human ocular cells.

Authors:  Jin-Zhong Zhang; Megan E Cavet; Karl R VanderMeid; Mercedes Salvador-Silva; Francisco J López; Keith W Ward
Journal:  Mol Vis       Date:  2009-12-08       Impact factor: 2.367
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.